Related Experiment Videos
[The preparation and study on hepatic targeting tendency of galactosyl-anti-CD3-McAb in mice]
1Department of Surgery, First Affiliated Hospital, WCUMS, Chengdu 610041, China.
Objective:
This study sought to reduce the recurrence rate of primary liver cacer (PLC) after hepatectomy by increasing the concentration of infiltrating lymphocytes(TILs) at the target organ.
Methods:
It has been reported that galactosyl-anti-CD3-McAb has an obvious hepatic targeting tendency in vitro. On the basis of that work, the present authors conducted a study in mice. Galactosyl-anti-CD3-McAb was prepared and its carbohydrate density was measured with the phenol-sulphyric acid method, and then anti-CD3-McAb (labeled with 125I) and galactosyl-anti-CD3-McAb (labeled with 131I) were infused respectively via the peripheral vein and the radioactivity in each organ was measured.
Results:
The carbohydrate density of galactosyl-anti-CD3-McAb in this experiment was 58.12, which effectively guaranteed the specific binding between galactosyl-anti-CD3-McAb and hepatic binding protein(HBP). It was also noticed that anti-CD3-McAb tended to aggregate in the lungs while being infused via the peripheral vein, and that galactosyl-anti-CD3-McAb had an obvious hepatic targeting tendency in vivo and it stayed in liver for quite a long period.
Conclusions:
Galactosyl-anti-CD3-McAb has an obvious hepatic targeting tendency in vivo while being infused through peripheral vein; this may be due to the specific binding between galactose and HBP.
Insights
Galactosyl-anti-CD3-McAb shows liver targeting ability in vivo, potentially improving liver cancer treatment by increasing tumor-infiltrating lymphocytes (TILs). This targeted approach may reduce primary liver cancer recurrence after surgery.
Area of Science:
- Immunology
- Hepatology
- Oncology
Background:
- Primary liver cancer (PLC) recurrence after hepatectomy remains a clinical challenge.
- Increasing tumor-infiltrating lymphocytes (TILs) at the liver is a strategy to reduce PLC recurrence.
- Galactosyl-anti-CD3-monoclonal antibody (McAb) has shown hepatic targeting in vitro.
Purpose of the Study:
- To evaluate the in vivo hepatic targeting of galactosyl-anti-CD3-McAb.
- To assess the potential of galactosyl-anti-CD3-McAb for enhancing TILs in the liver for PLC treatment.
Main Methods:
- Galactosyl-anti-CD3-McAb was prepared and its carbohydrate density measured.
- Anti-CD3-McAb (125I) and galactosyl-anti-CD3-McAb (131I) were infused intravenously in mice.
- Radioactivity in organs was measured to determine biodistribution and targeting.
Main Results:
- Galactosyl-anti-CD3-McAb demonstrated specific binding to hepatic binding protein (HBP) due to its carbohydrate density (58.12).
- Unmodified anti-CD3-McAb aggregated in the lungs.
- Galactosyl-anti-CD3-McAb exhibited significant hepatic targeting in vivo and prolonged retention in the liver.
Conclusions:
- Galactosyl-anti-CD3-McAb possesses in vivo hepatic targeting capability when administered intravenously.
- This targeting is likely mediated by the specific interaction between galactose moieties and hepatic binding protein (HBP).
- This targeted delivery system holds promise for improving liver cancer immunotherapy.